Skip to content

No results found

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

AVNS Avanos Medical, Inc.
$13.74 1.55% +0.21
Notify me if price changes either direction
Interactive Brokers Logotype

Buy AVNS stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 638.6M
Enterprise value 668.0M
Trailing PE 34.37234
Forward PE 10.816
PEG Ratio -0.34492104250871
Enterprise to EBITDA 12.28
Enterprise to revenue 0.953
Price to book MRQ 0.80711603
Price to sales TTM 0.8967269

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2025-12-31
Revenue (TTM) 701.2M
EBITDA 57.5M
Diluted EPS TTM -1.57
Total Cash (MRQ) 89.8M
Current ratio (MRQ) 2.151
Operating Cash Flow (TTM) 74.7M

AVNS trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent AVNS News

Home

No results found

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.